Everolimus-based immunosuppressive regimens in lung transplant recipients: impact on CMV infection.

[1]  B. Autran,et al.  CMV driven CD8(+) T-cell activation is associated with acute rejection in lung transplantation. , 2013, Clinical immunology.

[2]  L. Potena,et al.  Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation , 2013, Transplant infectious disease : an official journal of the Transplantation Society.

[3]  S. Baldi,et al.  Detection of human cytomegalovirus in transbronchial biopsies from lung transplant recipients , 2013, Archives of Virology.

[4]  M. Cooper,et al.  A comprehensive review of everolimus clinical reports: a new mammalian target of rapamycin inhibitor. , 2012, Transplantation.

[5]  N. Mueller,et al.  Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. , 2012, Transplantation.

[6]  D. Brennan,et al.  Cytomegalovirus Incidence Between Everolimus Versus Mycophenolate in De Novo Renal Transplants: Pooled Analysis of Three Clinical Trials , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[7]  D. Snydman,et al.  Update and review: state-of-the-art management of cytomegalovirus infection and disease following thoracic organ transplantation. , 2011, Transplantation proceedings.

[8]  A. Kirk,et al.  Cutting Edge: Rapamycin Augments Pathogen-Specific but Not Graft-Reactive CD8+ T Cell Responses , 2010, The Journal of Immunology.

[9]  R. Razonable,et al.  New Developments in the Management of Cytomegalovirus Infection after Solid Organ Transplantation , 2010, Drugs.

[10]  E. Vermes,et al.  Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study , 2010, Transplant infectious disease : an official journal of the Transplantation Society.

[11]  F. Patanè,et al.  Does everolimus associated with a low dose of cyclosporine in long-term cardiac transplant recipients improve renal function? Initial experience. , 2009, Transplantation proceedings.

[12]  R. Starling,et al.  A Lower Incidence of Cytomegalovirus Infection in De Novo Heart Transplant Recipients Randomized to Everolimus , 2007, Transplantation.

[13]  S. Baldi,et al.  Rapid shell vial culture for the detection of respiratory viruses from bronchoalveolar lavage in immunocompromised patients. , 2007, Panminerva medica.

[14]  V. Emery,et al.  Cytomegalovirus in transplantation – challenging the status quo , 2007, Clinical transplantation.

[15]  A. Webster,et al.  Target of Rapamycin Inhibitors (Sirolimus and Everolimus) for Primary Immunosuppression of Kidney Transplant Recipients: A Systematic Review and Meta-Analysis of Randomized Trials , 2006, Transplantation.

[16]  Gerald J Berry,et al.  Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[17]  W. Weimar,et al.  Three‐Year Efficacy and Safety Results from a Study of Everolimus Versus Mycophenolate Mofetil in de novo Renal Transplant Patients , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[18]  M. Zamora,et al.  Management of Cytomegalovirus Infection in Lung Transplant Recipients: Evidence-Based Recommendations , 2005, Transplantation.

[19]  H. Valantine,et al.  From clinical trials to clinical practice: an overview of Certican (everolimus) in heart transplantation. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[20]  E. Tuzcu,et al.  Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. , 2003, The New England journal of medicine.

[21]  A. Solé,et al.  Recommendations on the use of everolimus in lung transplantation. , 2013, Transplantation reviews.

[22]  T. Imamura,et al.  Successful conversion to everolimus after cytomegalovirus infection in a heart transplant recipient. , 2012, International heart journal.